Status:
COMPLETED
Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility:
All Genders
18+ years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) can be divided into pancreatic head cancer (PHC) and pancreatic body/tail cancer (PBTC) according to the anatomical position of tumors. There is increasing evid...
Eligibility Criteria
Inclusion
- Participants aged above 18 years.
- Patients who signed informed consent.
- PDAC patients diagnosed via postoperative pathology.
Exclusion
- Comorbidity with other cancers.
- Underwent preoperative chemotherapy, radiotherapy, or other biological treatment.
- Use of antibiotics, probiotics or prebiotics in the previous month.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06147154
Start Date
January 1 2022
End Date
December 31 2022
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250063